Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysis
Jacopo Mariotti(National Institutes of Health), Stéfania Bramanti(Istituti di Ricovero e Cura a Carattere Scientifico), Cristina Astrid Tentori(IRCCS Humanitas Research Hospital), Daniele Mannina(Humanitas University), Daniela Taurino(IRCCS Humanitas Research Hospital), Barbara Sarina(IRCCS Humanitas Research Hospital), Laura Giordano(Istituti di Ricovero e Cura a Carattere Scientifico), Armando Santoro(IRCCS Humanitas Research Hospital), Chiara Pinton(Humanitas University), Chiara De Philippis(IRCCS Humanitas Research Hospital)
Cited by 1
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
PD-1 Blockade in Anaplastic Thyroid Carcinoma
|Journal of Clinical Oncology|2020|349